^
    5d
    Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy (clinicaltrials.gov)
    P2, N=65, Completed, Hunan Cancer Hospital | Recruiting --> Completed | Trial completion date: Dec 2023 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib) • Anniko (penpulimab)
    10d
    A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy (clinicaltrials.gov)
    P2, N=118, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative
    |
    Focus V (anlotinib) • fulvestrant • Jingzhuda (entinostat)
    10d
    TQB2450-II-14: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. (clinicaltrials.gov)
    P2, N=71, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Nov 2025 | Recruiting --> Terminated; Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
    Trial completion date • Trial termination • IO biomarker
    |
    carboplatin • gemcitabine • paclitaxel • docetaxel • Focus V (anlotinib) • doxorubicin hydrochloride • Andewei (benmelstobart)
    12d
    Efficacy and Safety of Firmonertinib Plus Anlotinib as First-Line Treatment for Advanced NSCLC With EGFR Mutations: A Single-Arm, Phase I/II Trial. (PubMed, Clin Lung Cancer)
    Firmonertinib plus anlotinib demonstrated preliminary efficacy and manageable safety as first-line treatment among patients with NSCLC harboring EGFR mutations.
    P1/2 data • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation
    |
    Focus V (anlotinib) • Ivesa (firmonertinib)
    13d
    Multimodal treatment of radiation-associated laryngeal angiosarcoma: A case report and literature review. (PubMed, Medicine (Baltimore))
    Radiation-associated laryngeal angiosarcoma is exceptionally rare and portends a poor prognosis. This case illustrates the potential value of genomically informed multimodal therapy integrating chemotherapy, immunotherapy, and targeted agents; in our patient, toripalimab plus gemcitabine/nab-paclitaxel achieved a 9-month partial response. Further studies are needed to establish evidence-based treatment strategies for this understudied disease.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Avastin (bevacizumab) • gemcitabine • Focus V (anlotinib) • Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • pazopanib • albumin-bound paclitaxel • ifosfamide
    13d
    Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. (clinicaltrials.gov)
    P1/2, N=52, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)
    17d
    ALTN-Ⅱ-01: Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Dec 2026 | Trial primary completion date: Oct 2023 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib) • temozolomide
    21d
    Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs. (PubMed, Ther Adv Med Oncol)
    We aimed to assess the efficacy, safety, and potential biomarkers of anlotinib plus TQB2450 in patients with advanced HCC. Elevated serum BDNF levels might serve as a potential positive prognostic marker and, together with ECOG score, may help complement the CRAFITY score in identifying subgroups that could benefit from ICIs and antiangiogenic therapy. This study was registered on ClinicalTrials.gov (NCT03825705, registered January 31, 2019).
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    AFP (Alpha-fetoprotein) • BDNF (Brain Derived Neurotrophic Factor) • CRP (C-reactive protein)
    |
    Focus V (anlotinib) • Andewei (benmelstobart)
    26d
    Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (clinicaltrials.gov)
    P3, N=566, Recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • paclitaxel • Focus V (anlotinib) • TQB2868
    28d
    Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors. (PubMed, BMC Cancer)
    To date, chemotherapy-based treatments remain the standard of care for C797S + NSCLC patients resistant to third-generation EGFR TKIs. However, for T790M-/C797S + patients received a third-generation EGFR TKI as first-line therapy, EGFR-TKI rechallenge, involving a combination of first and third-generation EGFR TKIs or first/second-generation TKIs, may be an optimal strategy.
    Preclinical • Journal • Real-world evidence • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Focus V (anlotinib) • Alunbrig (brigatinib)
    30d
    Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC (clinicaltrials.gov)
    P2, N=69, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab) • Focus V (anlotinib) • Andewei (benmelstobart) • Anfangning (garsorasib)
    1m
    QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
    New P2 trial
    |
    cisplatin • carboplatin • Focus V (anlotinib) • Qibeian (iparomlimab/tuvonralimab)